| HOME >> BIOLOGY >> TECHNOLOGY |
All statements in this press release that are not historical are
forward- looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, including statements regarding Orchid
Cellmark's expectations with respect to Mr. Smith's knowledge, skills and
role in the company. Such statements are subject to the risks and
uncertainties that could cause actual results to differ materially from
those projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost
and pricing of Orchid Cellmark's products and services, dependence on
government funding and collaborations, regulatory approvals, competition,
intellectual property of others, patent protection, litigation, the timing
of release of federal funds, the timing and amount of contracts put up for
bid, Orchid Cellmark's ability to timely and successfully initiate
operational efficiencies, lower overhead and other remedial measures and
Orchid's continued relationship with DEFRA. These risks and other
additional factors affecting these statements and Orchid Cellmark's
business are discussed under the headings "Risks Related to Our Business"
and "Risks Associated with Our Common Stock" in Orchid Cellmark's Annual
Report on Form 10-K for the year ended December 31, 2006, as filed with the
Sec
'/>"/>
| SOURCE Orchid Cellmark Inc. Copyright©2007 PR Newswire. All rights reserved |